Title:
AGENT FOR TOPICAL ADMINISTRATION
Document Type and Number:
WIPO Patent Application WO/2006/137421
Kind Code:
A1
Abstract:
An agent for topical administration comprising a compound having a P38MAPK (Mitogen-Activated Protein Kinase) inhibitory effect or a pharmacologically salt thereof as an active ingredient, wherein, when the agent is administered topically, the concentration of the compound or salt at the topically administered site is 350 times or more higher than that in the blood plasma. In the agent for topical administration, the compound having the P38MAPK inhibitory effect may be, for example, a phenol derivative or a fused heterocyclic compound having a phenol structure in the fused ring system.
Inventors:
IKEMURA TOSHIHIDE
OHSHIMA ETSUO
HORIKOSHI KAORI
OHTSUKA SATOKO
MORI KIYOTOSHI
KUSAKA HIROKO
OHSHIMA ETSUO
HORIKOSHI KAORI
OHTSUKA SATOKO
MORI KIYOTOSHI
KUSAKA HIROKO
Application Number:
PCT/JP2006/312378
Publication Date:
December 28, 2006
Filing Date:
June 21, 2006
Export Citation:
Assignee:
KYOWA HAKKO KOGYO KK (JP)
IKEMURA TOSHIHIDE
OHSHIMA ETSUO
HORIKOSHI KAORI
OHTSUKA SATOKO
MORI KIYOTOSHI
KUSAKA HIROKO
IKEMURA TOSHIHIDE
OHSHIMA ETSUO
HORIKOSHI KAORI
OHTSUKA SATOKO
MORI KIYOTOSHI
KUSAKA HIROKO
International Classes:
A61K45/00; A61K31/517; A61P1/00; A61P1/02; A61P1/04; A61P9/10; A61P11/00; A61P11/02; A61P11/06; A61P17/00; A61P17/06; A61P17/10; A61P25/00; A61P25/04; A61P25/16; A61P25/28; A61P27/02; A61P27/04; A61P27/06; A61P27/12; A61P27/14; A61P35/00; A61P37/08; A61P43/00; C07D239/84; C07D403/12; C07D405/12; C07D413/14
Domestic Patent References:
| WO2004089929A1 | 2004-10-21 | |||
| WO2004060306A2 | 2004-07-22 | |||
| WO2003084503A2 | 2003-10-16 | |||
| WO2002060869A2 | 2002-08-08 | |||
| WO2002032862A2 | 2002-04-25 | |||
| WO2001038312A1 | 2001-05-31 | |||
| WO2001038313A1 | 2001-05-31 | |||
| WO2001038314A1 | 2001-05-31 | |||
| WO2001037837A1 | 2001-05-31 | |||
| WO2004092144A2 | 2004-10-28 |
Other References:
TAKANAMI-OHNISHI Y. ET AL.: "Essential role of p38 mitogen-activated protein kinase in contact hypersensitivity", J. BIOL. CHEM., vol. 277, no. 40, 2002, pages 37896 - 37903, XP002378292
KASUYA Y. ET AL.: "Essential role of p38 mitogen-activated protein kinase in contact hypersensitivity", FASEB JOURNAL, vol. 17, no. 4 TO 5, 2003, pages A606 + ABSTRACT NO. 377.26, XP008074198
BACHELOR M.A. ET AL.: "Inhibition of p38 mitogen-activated protein kinase and phospahtidylinositol 3-kinase decreases UVB-induced activator protein-1 and cyclooxygenase-2 in a SKH-1 hairless mouse model", MOL. CANCER RES., vol. 3, no. 2, 2005, pages 90 - 99, XP003005413
DUAN W. ET AL.: "Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice", AM. J. RESPIR. CRIT. CARE MED., vol. 11, no. 6, March 2005 (2005-03-01), pages 571 - 578, XP003005414
KASUYA Y. ET AL.: "Essential role of p38 mitogen-activated protein kinase in contact hypersensitivity", FASEB JOURNAL, vol. 17, no. 4 TO 5, 2003, pages A606 + ABSTRACT NO. 377.26, XP008074198
BACHELOR M.A. ET AL.: "Inhibition of p38 mitogen-activated protein kinase and phospahtidylinositol 3-kinase decreases UVB-induced activator protein-1 and cyclooxygenase-2 in a SKH-1 hairless mouse model", MOL. CANCER RES., vol. 3, no. 2, 2005, pages 90 - 99, XP003005413
DUAN W. ET AL.: "Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice", AM. J. RESPIR. CRIT. CARE MED., vol. 11, no. 6, March 2005 (2005-03-01), pages 571 - 578, XP003005414
Download PDF:
Previous Patent: IMAGE PROCESSING DEVICE AND METHOD, IMAGING DEVICE, AND COMPUTER PROGRAM
Next Patent: PRESSURE STATUS DISPLAY DEVICE
Next Patent: PRESSURE STATUS DISPLAY DEVICE